Solid Biosciences Inc. insider trading
Every open-market purchase and sale by Solid Biosciences Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Solid Biosciences Inc.’s insiders pay?
From March 28, 2019 to November 13, 2025, 19 insiders reported 8 open-market purchases and 16 sales not made under a pre-set plan in Solid Biosciences Inc. Twelve months after each purchase was reported, the shares were −56.1% against the S&P 500 on average (median −77.3%), over 8 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −73.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 30, 2019 into $485 by November 2, 2026, −34.1% a year. It held shares 55% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,685 (+10.6% a year), and held throughout $27,931 (+15.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Ganot Ilan | CEO & President | 0 | — | — | 3 | −102.4% (1) | November 13, 2025 |
| Brooks Gabriel | Chief Medical Officer | 0 | — | — | 2 | −12.6% (2) | October 21, 2025 |
| Edelman Joseph | Director | 2 | −48.5% (2) | 0% | 0 | — | February 21, 2025 |
| Tan Kevin | CFO & Treasurer | 0 | — | — | 2 | −85.2% (1) | January 13, 2025 |
| Atchinson Robert | 10% owner | 1 | −15.3% (1) | 0% | 0 | — | February 19, 2025 |
| Bcls Sb Investco, LP | 10% owner | 1 | −4.3% (1) | 0% | 0 | — | February 21, 2025 |
| Boxer Capital, LLC | 10% owner | 0 | — | — | 1 | −69.4% (1) | March 28, 2019 |
| Cumbo Alexander | President and CEO | 0 | — | — | 1 | — | December 4, 2024 |
| Hanrahan Jessie | Chief Regulatory Officer | 0 | — | — | 1 | — | December 4, 2024 |
| Herscha Lynette | Chief Legal Officer | 0 | — | — | 1 | — | July 29, 2020 |
| Herzich Paul | Chief Technology Officer | 0 | — | — | 1 | — | December 4, 2024 |
| Howton David T | Chief Operating Officer | 0 | — | — | 1 | — | December 4, 2024 |
| Kolchinsky Peter | Director | 1 | −92.6% (1) | 0% | 0 | — | March 23, 2021 |
| Morris Carl Ashley | Chief Scientific Officer | 0 | — | — | 1 | −102.4% (1) | January 29, 2021 |
| Perceptive Advisors LLC | Director | 1 | −69.0% (1) | 0% | 0 | — | July 29, 2019 |
| Perceptive Xontogeny Venture Fund, LP | Director | 1 | −85.5% (1) | 0% | 0 | — | January 12, 2024 |
| Ra Capital Nexus Fund, L.P. | Director | 1 | −85.5% (1) | 0% | 0 | — | January 12, 2024 |
| Schneider Joel Solomon Zev | Chief Technology Officer | 0 | — | — | 1 | −102.4% (1) | January 29, 2021 |
| Ziolkowski Jennifer Lynn | CFO, Treasurer & Asst. Secy | 0 | — | — | 1 | −102.4% (1) | January 29, 2021 |
When several insiders traded Solid Biosciences Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Solid Biosciences Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −30.9% against the index. After 1 selling crowd, −84.7%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 31, 2024 | 2 buying | +34.5% | +12.2% | −79.7% |
| April 30, 2021 | 2 buying | −50.6% | −74.0% | −89.0% |
| February 26, 2021 | 4 selling | −62.3% | −84.7% | −105.9% |